Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Menu
Subscribe
Sign In
Register
Portfolio
Corner Office
Culture
Premium
Opinion
Research
Video
Innovation
Search Query
Submit Search
Show Search
Pharmaceutical
Premium
How ValueAct Shook Off Its Big Loss from Valeant
The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.
Stephen Taub
January 6, 2017
Portfolio
Daily Agenda: Markets Surprised as Bank of Japan Holds Firm
U.S. markets slowest GDP growth in two years; Nikkei sell-off; Abbott Labs to buy St. Jude Medical; more earnings beats.
Andrew Barber
April 28, 2016
Portfolio
Daily Agenda: Bond Markets Mull September or December Fed Hike
Mixed economic data from Europe; Shire makes a hostile bid for Baxalta; Neiman Marcus readies for IPO.
Andrew Barber
August 5, 2015